Replies to post #1650 on SELLAS Life Sciences Group Inc (SLS)

[casenumber]

U mean this?

“Sellas recently kicked off a phase 1/2 combination trial of GPS with Merck’s Keytruda, the company said. It is testing the combo in patients with acute myeloid leukemia (AML), as well as those with ovarian cancer, triple-negative breast cancer, small-cell lung cancer and colorectal cancer. It’s also planning a phase 3 study pitting GPS as a single agent against the investigator’s choice of best maintenance therapy in AML patients after they’ve had success with second-line antileukemic therapy. “

[pberger]

TOXIC FINANCING ruined this stock.
Trading like a hopeless turd even if the pipeline is excellent.
Such is the power of TOXIC FINANCING.